Dana-farber-cancer Institute Inc.

Genus Oncology, LLC

Arch Development Corporation

University of Chicago

Other

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Genzyme Corporation

Beth Israel Deaconess Medical Center, Inc.

Adherex Technologies, Inc.

Therion Biologics Corporation

Amira, Inc.

Hillstream Biopharma, Inc.

Xyone Therapeutics Inc.

Donald W Kufe

Surender Kharbanda

Dennis E Hallahan

Vikas P Sukhatme

Rima Kaddurah-Daouk

Miyako Abe

Jianlin Gong

Tomio Takeuchi

Jeffrey Schlom

Takeo Yoshioka

Bernard Roizman

Ralph R Weichselbaum

Masaaki Ishizuka

Dennis L Panicali

Linda R Gritz

Judith A Kantor

Thomas Spector

Tsuneya Ohno

Beverly A Teicher

Brian Huber

Hiroyuki Kumagai

Naoki Agata

James O Park

Harpal Singh

Mitchell Posner

Steven J Chmura

Steven Chmura

Jose Quintans

Helena Mauceri

David Avigan

Vasundhara Shukla

Corinne L Reimer

Mary E Dolan

Yoshinobu Manome

Howard A Fine

Jacalyn Rosenblatt

William Paul Peters

Ralph H Weichselbaum

Bakhtiar Yamini

Gregory S Sibley

Vinay Gupta

Helen Mauceri

James Park

The present invention relates to polymeric nanoparticles comprising a cytokine or a nucleic acid encoding for a cytokine, pharmaceutical compositions comprising the same, and methods for treating certain diseases comprising administering these polymeric nanoparticles to a subject in need thereof.

Polymeric nanoparticles providing nucleic acids encoding TNF-&#x3b1;

The present invention is directed to antibodies binding to MUC1-C/extracellular domain (MUC1-C/ECD) and methods of using such antibodies to treat cancers that express the MUC1 antigen.

Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)

The present invention provides compositions and methods for treating cancer.

Compositions and methods of treating cancer

The present disclosure is directed to antibodies binding to MUC1-C/extracellular domain (MUC1-C/ECD) and methods of using such antibodies to treat cancers that express the MUC1 antigen.

The treatment of human epidermal growth factor receptor 2-positive (HER2+) cancers using a combination of anti-mucin 1 (anti-MUC1) therapy and anti-human epidermal growth factor receptor 2 (anti-HER2) therapy is described, such as the treatment of trastuzamab-resistant cancers, both primary and acquired, using the same combination of agents.

Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics

Compositions comprising SEQ ID NO: 1 and methods of treating a MUC16-expressing tumor cell are described.

Compositions and methods for treating cancer

The invention provides for treatment of MUC1+/ER&#x3b1;+/&#x2212; cancers using an anti-MUC1 therapy, optionally including an anti-ER&#x3b1; therapy. In particular, the invention addresses the treatment of tamoxifen-resistant cancers, using MUC1+, and optionally anti-ER&#x3b1; therapy.

Combination anti-estrogen receptor cancer therapy using MUC1 peptides and chemotherapeutics

Peptides from the Mucin 1 (MUC1) cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.

MUC-1 cytoplasmic domain peptides as inhibitors of cancer

The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-&#x3ba;B or a STAT, and block inflammatory response mediated by NF-&#x3ba;B or STAT signaling.

Inhibition of inflammation using antagonists of MUC1

The invention provides method of treating cancers that express mucin 1 (MUC1) by the administration of phosphatidylinositol 3-kinase (PI3-K) inhibitors in combination with MUC1-directed cancer therapies. The PI3-K inhibition may advantageously be combined with peptides that inhibit MUC1 oligomerization, or further with other standard anticancer therapies such as chemo-, radio- and surgical therapies.

Treating MUC1-expressing cancers with combination therapies

Peptides from the MUC1 cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.

The invention provides methods for the identification of small molecules that inhibit MUC1 oligomerization, and the functions flowing therefrom. In addition, small molecules that prevent MUC1 oligomerization are disclosed. Identified molecules will find use in treating a variety of MUC1-related inflammatory conditions, including MUC1-related cancers.

Small molecule inhibitors of MUC1 and methods of identifying the same

The disclosure features a variety of compositions and methods for modulating an interaction between MUC1 and caspase-8 and/or an interaction between MUC1 and a DED-containing protein (e.g., an anti-apoptotic DED-containing protein or a pro-apoptotic DED-containing protein). Such methods and compositions are useful for the treatment or prevention of e.g., a variety of pathological disorders characterized by elevated or decreased levels of apoptosis. Moreover, the compositions and methods are also useful to identify, design, and generate compounds that modulate the interactions. The compounds and/or pharmaceutical compositions containing the compounds can be used in the treatment of disease.

MUC1, caspase-8, and DED-containing proteins

The present invention is directed to improved compositions for cellular delivery of peptides. Using segments of only 3-5 positively-charged residues, one can effectively transfer peptides, including therapeutic peptides, into cells. Also provided are modified peptides such as those include stapled and cyclized peptide technology, as well as peptoids/peptidomimetics.

Antagonists of MUC1

Growing community of inventors

Wellesley, MA, United States of America

Donald W Kufe